Primary therapy and survival in patients with Burkitt lymphoma in The Netherlands: a population-based study, 1989-2018.

Issa, D E; Seefat, R L; Visser, O; Zweegman, S; Lugtenburg, P J; Dinmohamed, A G; Chamuleau, M E D

Issa, D E; Seefat, R L; Visser, O; Zweegman, S; Lugtenburg, P J; Dinmohamed, A G; Chamuleau, M E D.

Afiliação

Issa DE; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU Medical Center, Amsterdam, The Netherlands.
Seefat RL; Department of Hematology, Jeroen Bosch Hospital, Den Bosch, The Netherlands.
Visser O; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU Medical Center, Amsterdam, The Netherlands.
Zweegman S; Department of Registration, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.
Lugtenburg PJ; Department of Hematology, Jeroen Bosch Hospital, Den Bosch, The Netherlands.
Dinmohamed AG; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Chamuleau MED; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU Medical Center, Amsterdam, The Netherlands.

Blood ; 137(20): 2848-2851, 2021 05 20.

Article em En | MEDLINE | ID: mdl-33512487

Assuntos

Linfoma de Burkitt; Linfoma de Burkitt/tratamento farmacológico; Linfoma de Burkitt/epidemiologia; Ciclofosfamida; Humanos; Países Baixos/epidemiologia; Vincristina

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma de Burkitt Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google